Yesid Alvarado

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Nitin Jain, Michael J. Keating, Philip A. Thompson et al. · New England Journal of Medicine · 2019 · 491 citations · Full text

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

Courtney D. DiNardo, Abhishek Maiti, Caitlin R. Rausch et al. · The Lancet Haematology · 2020 · 325 citations · Full text

Hematological Malignancy, Medicine, Mixed-phenotype Acute Leukemia +9

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Courtney D. DiNardo, Curtis A. Lachowiez, Koichi Takahashi et al. · Journal of Clinical Oncology · 2021 · 321 citations · Full text

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

Hagop M. Kantarjian, Farhad Ravandi, Nicholas J. Short et al. · The Lancet Oncology · 2018 · 238 citations · Full text

Inotuzumab Ozogamicin, Hematological Malignancy, Medicine +10

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

Elias Jabbour, Nicholas J. Short, Nitin Jain et al. · The Lancet Haematology · 2022 · 215 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +6